Patient-Oriented Evidence That Matters
Injectable Extended-Release Naltrexone Effective for Opioid Use Disorder
Am Fam Physician. 2018 Jun 15;97(12):819.
Is injectable extended-release naltrexone (Vivitrol) as effective as daily oral buprenorphine/naloxone (Suboxone) for preventing relapse in adults with opioid use disorder?
Injectable extended-release naltrexone administered every four weeks is similar in efficacy to daily oral buprenorphine/naloxone for the treatment of opioid use disorder. Patients using extended-release naltrexone reported higher satisfaction with treatment and were more likely to recommend it to others. (Level of Evidence = 1b–)
The use of oral medications to treat opioid use disorder is fraught with low adherence and a high dropout rate. These investigators identified 159 adults, 18 to 60 years of age, who met standard diagnostic criteria for opioid use disorder. Study participants randomly received (concealed allocation assignment) ora l buprenorphine/naloxone, 4 to 24 mg per day administered in a controlled environment, or intramuscular extended-release naltrexone, 380 mg every four weeks. Although individuals who assessed outcomes were not masked to treatment group assignments, individual primary outcomes were objective and minimally prone to biased reporting (e.g., study retention rate, number of days with negative urine drug tests, number of days of heroin and other illicit opioid use). Missing urine drug tests was considered positive for opioids. Complete follow-up occurred for 66% of participants at 12 weeks. More individuals in the daily buprenorphine/naloxone group failed to complete follow-up than in the extended-release naltrexone group (23 vs. 15, respectively).
Using intention-to-treat analysis, no significant differences occurred between the extended-release naltrexone group and the oral buprenorphine/naloxone group in study retention time, negative opioid urine drug tests, and days of heroin and other illicit opioid use. Similarly, no group differences occurred in the use of amphetamines, cocaine, alcohol, cannabis, or injected drugs. Significantly more patients in the extended-release naltrexone group had a reduction in days of benzodiazepine use and higher reported satisfaction, and significantly more were likely to recommend their treatment to others. No significant differences occurred in dropout rates due to adverse events.
Study design: Randomized controlled trial (single-blinded)
Funding source: Foundation
Setting: Outpatient (specialty)
Reference: Tanum L, Solli KK, Latif ZE, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197–1205.
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Editor-in-Chief.
A collection of POEMs published in AFP is available at http://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Jul 1, 2020
Access the latest issue of American Family Physician